Carcinoma, Non-Small-Cell Lung

<section class="Section" data-sectioncode="34089-3"><a name="S11"></a><a name="section-9"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">Dacomitinib is an oral kinase inhibitor with a molecular formula of C<span class="Sub">24</span>H<span class="Sub">25</span>ClFN<span class="Sub">5</span>O<span class="Sub">2</span> ∙ H<span class="Sub">2</span>O and a molecular weight of 487.95 Daltons. The chemical name is: (2<span class="Italics">E</span>)-<span class="Italics">N</span>-{4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}-4-(piperidin-1-yl)but-2-enamide monohydrate and its structural formula is:</p><div class="Figure"><a name="id1558"></a><img alt="Chemical Structure" src="vizimpro-01.jpg"/></div><p>Dacomitinib is a white to pale yellow powder.</p><p>VIZIMPRO tablets contain 45, 30, or 15 mg of dacomitinib with the following inactive ingredients in the tablet core; lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, and magnesium stearate. The film coating consists of Opadry II<span class="Sup">®</span> Blue 85F30716 containing: Polyvinyl alcohol – partially hydrolyzed, Talc, Titanium dioxide, Macrogol/PEG 3350, and FD&amp;C Blue #2/Indigo Carmine Aluminum Lake. </p></section>

Vizimpro

dacomitinib

dacomitinib 15 MG Oral Tablet

dacomitinib 15 MG Oral Tablet [Vizimpro]

dacomitinib 30 MG Oral Tablet

dacomitinib 30 MG Oral Tablet [Vizimpro]

dacomitinib 45 MG Oral Tablet

dacomitinib 45 MG Oral Tablet [Vizimpro]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Report Adverse Event 

Prescribing Information

Medication Guide 

Submit MSL Request 

Pharmacy List 

Reimbursement Information 

Coverage Authorization Request 

Coverage Authorization Appeals 

Letter of Medical Necessity 

Formulary Exception Letter 

PA Checklist 

Appeals Checklist 

Other HCP Resources - Access 

Pfizer Oncology Together Form 

Pfizer Oncology Together Form - Spanish 

Enroll in Patient Savings Program 

Pfizer Patient Assistance Program 

Free 90-day Supply: For Uninsured Patients While Applying for Medicaid

HCP Office : Attest & Print Co-Pay Card 

Pfizer Oncology Patient Access Guide

Pfizer Oncology Patient Access Guide - Spanish 

Online Sample Form 

Other HCP Resources 

About Vizimpro

Taking Vizimpro

Side Effects 

Patient Resources 

Patient Brochure 

What To Expect With Vizimpro Brochure 

Instructions For Use: Metastatic Non-small Cell Lung Cancer (NSCLC) EGFR+

NCCN Recommendations

Personalized Support 